Zai Lab Ltd - Asset Resilience Ratio
Zai Lab Ltd (ZLAB) has an Asset Resilience Ratio of 0.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Zai Lab Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Zai Lab Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Zai Lab Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zai Lab Ltd (ZLAB) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.00 Million | 0.91% |
| Total Liquid Assets | $10.00 Million | 0.91% |
Asset Resilience Insights
- Limited Liquidity: Zai Lab Ltd maintains only 0.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zai Lab Ltd Industry Peers by Asset Resilience Ratio
Compare Zai Lab Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Zai Lab Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Zai Lab Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.85% | $10.00 Million | $1.17 Billion | -26.98pp |
| 2024-12-31 | 27.83% | $330.00 Million | $1.19 Billion | +26.26pp |
| 2023-12-31 | 1.57% | $16.30 Million | $1.04 Billion | -- |
| 2022-12-31 | 0.00% | $0.00 | $1.22 Billion | -- |
| 2021-12-31 | 27.64% | $445.00 Million | $1.61 Billion | -29.75pp |
| 2020-12-31 | 57.39% | $744.68 Million | $1.30 Billion | +1.07pp |
| 2019-12-31 | 56.31% | $200.00 Million | $355.15 Million | -10.03pp |
| 2018-12-31 | 66.34% | $200.35 Million | $301.99 Million | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more